The US Food and Drug Administration’s seven-year delay in updating guidance on social media promotion of prescription drugs has garnered the attention of two Senators, who want new guidance by the end of December.
In a 14 February letter to FDA Commissioner Robert Califf, Senate Judiciary Committee chair Richard Durbin, D-IL, and Sen....
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?